OncoVista Innovative Therapies

OVIT

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$2,356

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+5.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.5M (2010) → 21.7M (2014)

OncoVista Innovative Therapies is a small biotechnology company focused on developing cancer treatments. It works on experimental drugs aimed at fighting tumors, with potential customers being hospitals, oncologists, and cancer patients. The company operates in the clinical-stage biotech space, meaning it is still testing its therapies and has not yet brought a product to market.

OncoVista does not currently generate meaningful revenue, which is typical for early-stage drug developers that rely on funding and partnerships rather than product sales. The company is very small, with a market cap near zero, and operates primarily in the United States. The main risk it faces is the high failure rate of clinical drug trials — most experimental cancer drugs do not receive regulatory approval, and without a successful trial result or outside funding, a company this size can struggle to survive.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-200.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$669,405/ year

↓ Declining (-26% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.0%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~7 months

$61,270 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

OncoVista Innovative Therapies has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial